Literature DB >> 23916803

Prognosis of unexpected and expected pathologic N1 non-small cell lung cancer.

Sumin Shin1, Hong Kwan Kim, Yong Soo Choi, Kwhanmien Kim, Jhingook Kim, Young Mog Shim.   

Abstract

BACKGROUND: This study was undertaken to compare clinicopathologic features and survival between patients with unexpected N1 (clinical N0-pathologic N1) and expected N1 disease (clinical N1-pathologic N1) after operation for non-small cell lung cancer.
METHODS: From 2003 to 2009, 305 patients who were found to have pathologic N1 disease after complete resection were retrospectively analyzed. Among these, 177 patients had negative findings for both computed tomography (CT) and positron emission tomography (PET)/CT (group cN0). Sixty-eight patients had negative CT and positive PET/CT or positive CT and negative PET/CT findings (group cN0-1). Sixty patients had positive findings for both CT and PET/CT (group cN1).
RESULTS: Patients in the cN1 group had larger tumors (p<0.001), greater pathologic T stage (p=0.018), and greater percentage of squamous cell carcinoma (p<0.001) than did those in the other groups. Patients in the cN1 group had a greater number of positive N1 lymph nodes (p=0.004) and more frequent extracapsular nodal invasion (p<0.001). The 5-year overall survival was 66%, 63%, and 58% in groups cN0, cN0-1, and cN1, respectively (cN0 vs cN0-1, p=0.958; cN0 vs cN1, p=0.038). The 5-year disease-free survival was 54%, 52%, and 39% in groups cN0, cN0-1, and cN1, respectively (cN0 vs cN0-1, p=0.862; cN0 vs cN1, p=0.01).
CONCLUSIONS: Patients with unexpected N1 disease showed better survival than did those with expected N1 disease, which seemed to be related to the pathologically minimal extent of the primary tumor and nodal involvement.
Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  10

Mesh:

Year:  2013        PMID: 23916803     DOI: 10.1016/j.athoracsur.2013.04.070

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  9 in total

1.  Clinicopathologic correlates of postoperative N1 or N2 nodal upstaging in non-small cell lung cancer.

Authors:  Youngkyu Moon; Kyo Young Lee; Kyung Soo Kim; Jae Kil Park
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

2.  Prognostic factors for surgically managed patients with stage II non-small cell lung cancer.

Authors:  Liming Wang; Yang Liu; Shun Xu
Journal:  Int J Clin Exp Med       Date:  2015-01-15

3.  Histological type predicts mediastinal metastasis and surgical outcome in resected cN1 non-small cell lung cancer.

Authors:  Tetsuya Mizuno; Takaaki Arimura; Hiroaki Kuroda; Noriaki Sakakura; Yasushi Yatabe; Yukinori Sakao
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-06-28

4.  Comparison of prognostic values of primary tumor and nodal 18F-fluorodeoxyglucose uptake in non-small cell lung cancer with N1 disease.

Authors:  Chae Hong Lim; Seung Hyup Hyun; Seung Hwan Moon; Young Seok Cho; Joon Young Choi; Kyung-Han Lee
Journal:  Eur Radiol       Date:  2019-03-21       Impact factor: 5.315

5.  Prognostic factor and treatment strategy for clinical N1 non-small cell lung cancer.

Authors:  Masaya Tamura; Isao Matsumoto; Yusuke Tanaka; Daisuke Saito; Shuhei Yoshida; Munehisa Takata; Hirofumi Takemura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-09-18

6.  Predicted extracapsular invasion of hilar lymph node metastasis by fusion positron emission tomography/computed tomography in patients with lung cancer.

Authors:  Takashi Makino; Yoshinobu Hata; Hajime Otsuka; Satoshi Koezuka; Kazutoshi Isobe; Nobumi Tochigi; Nobuyuki Shiraga; Kazutoshi Shibuya; Sakae Homma; Akira Iyoda
Journal:  Mol Clin Oncol       Date:  2015-07-01

Review 7.  Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis.

Authors:  Claudio Luchini; Nicola Veronese; Alessia Nottegar; Monica Cheng; Takuma Kaneko; Camilla Pilati; Fabrizio Tabbò; Brendon Stubbs; Antonio Pea; Fabio Bagante; Jacopo Demurtas; Matteo Fassan; Maurizio Infante; Liang Cheng; Aldo Scarpa
Journal:  Virchows Arch       Date:  2018-02-01       Impact factor: 4.064

8.  Skip metastasis in mediastinal lymph node is a favorable prognostic factor in N2 lung cancer patients: a meta-analysis.

Authors:  Zihuai Wang; Jiahan Cheng; Wenyu Huang; Diou Cheng; Yilin Liu; Qiang Pu; Nathan E Reticker-Flynn; Lunxu Liu
Journal:  Ann Transl Med       Date:  2021-02

9.  Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer.

Authors:  Hyunju Shin; Jae Myoung Noh; Hongryull Pyo; Yong Chan Ahn; Dongryul Oh
Journal:  Radiat Oncol J       Date:  2021-03-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.